PI3K Inhibitor and Paclitaxel Combination for Head and Neck Cancer
Solution Overview
Problem
Current treatments for head and neck squamous cell carcinoma, particularly those resistant to prior therapies, have limited effectiveness, leading to poor prognosis and quality of life for patients, with a need for more targeted and effective therapies.
Innovation Solution
A pharmaceutical combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor compound and paclitaxel, administered simultaneously, separately, or sequentially, to target the PI3K pathway in head and neck cancers, including those resistant to prior treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy treatments are used for head and neck squamous cell carcinoma, then initial response rates are high, but treatment effectiveness deteriorates at relapse with poor survival outcomes
Solution Approach 1:
The patent combines paclitaxel (a chemotherapy agent) with a PI3K inhibitor (a targeted therapy) to create a combination treatment regimen. This merging of conventional chemotherapy with targeted molecular therapy addresses the limitation of single-agent chemotherapy by attacking cancer through multiple mechanisms simultaneously, thereby improving treatment effectiveness at relapse and potentially extending survival time in head and neck squamous cell carcinoma patients
2Reliability
If aggressive chemotherapy therapy is administered, then initial tumor response is improved, but recurrence rate increases to 35-50%
Solution Approach 1:
The combination of paclitaxel and PI3K inhibitor creates a multi-targeted approach that addresses both initial tumor control and prevention of recurrence. The PI3K inhibitor component specifically targets the molecular pathways that drive cancer cell survival and proliferation, complementing paclitaxel's microtubule-stabilizing effects, thereby reducing recurrence rates while maintaining high initial response rates
3Ease of operation
If single-agent chemotherapy is used, then treatment simplicity is maintained, but therapeutic efficacy is limited particularly in resistant cases
Solution Approach 1:
The patent merges paclitaxel with a PI3K inhibitor to create a combination therapy that maintains relative treatment simplicity through standardized administration protocols while dramatically improving therapeutic efficacy. The combination regimen provides a systematic approach that is easier to implement than multiple separate therapies, yet delivers superior results particularly in paclitaxel-resistant head and neck squamous cell carcinoma cases
Data Source
Figure 1
Figure 2
AI summary
A pharmaceutical combination comprising (a) a phosphatidylinositol-3-kinase (PI3K) inhibitor compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof and (b) paclitaxel or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use, for the treatment of a cancer of the head and neck; a pharmaceutical composition comprising said combination; the use of said combination for the preparation of a medicament for the treatment of a cancer of the head and neck; a method of treating or preventing a cancer of the head and neck comprising administering a jointly therapeutically effective amount of such a combination to a subject in need thereof; and a commercial package thereof.
